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Abstract
Initial establishment of the human gut microbiota is generally believed to occur immediately following birth,
involving key gut commensals such as bifidobacteria that are acquired from the mother. The subsequent
development of this early gut microbiota is driven and modulated by specific dietary compounds present in
human milk that support selective colonization. This represents a very intriguing example of host-microbe co-
evolution, where both partners are believed to benefit. In recent years, various publications have focused on
dissecting microbial infant gut communities and their interaction with their human host, being a determining
factor in host physiology and metabolic activities. Such studies have highlighted a reduction of microbial diversity
and/or an aberrant microbiota composition, sometimes referred to as dysbiosis, which may manifest itself during
the early stage of life, i.e., in infants, or later stages of life. There are growing experimental data that may explain
how the early human gut microbiota affects risk factors related to adult health conditions. This concept has fueled
the development of various nutritional strategies, many of which are based on probiotics and/or prebiotics, to
shape the infant microbiota. In this review, we will present the current state of the art regarding the infant gut
microbiota and the role of key commensal microorganisms like bifidobacteria in the establishment of the first
microbial communities in the human gut.
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Introduction
The human gastrointestinal tract (GIT) harbors a wide
array of microorganisms, which constitute a complex mi-
crobial ecosystem, known as gut microbiota, which
reaches its highest microbial density in the colon. The gut
microbiota is believed to play (a) key role(s) in maintain-
ing and supporting human health, and any disturbance in
its composition, sometimes referred to as intestinal dys-
biosis, is believed to facilitate the onset of and/or aggravate
certain diseases, including autoimmune and allergic dis-
eases, colorectal cancer, metabolic diseases and bacterial
infections. Indigestible food components, i.e., prebiotics,
as well as the use of health-promoting viable microorgan-
isms, i.e., probiotics, are often used as biotherapeutic
agents in order to re-establish/maintain normal homeosta-
sis of the gut microbiota [for a review see [1]].
The extent of microbiota composition and diversity has
only recently been made possible through the use of
culture-independent based approaches, known as metage-
nomics, aimed at revealing the presence of microbes based
on their DNA sequences. Part of the microorganisms that
reside in the intestine can be cultivated [2, 3], though up
to 50% of the microbial population is currently considered
unculturable [4–6]. The first metagenomics-based survey
of the fecal microbiota of healthy humans highlighted the
extraordinarily high microbial diversity of this environ-
ment with the discovery of a considerable number of phy-
lotypes, many of which did not correspond to cultured
strains from bacterial collections [7]. Recently, metage-
nomic data sets have provided a more precise view of the
complexity of the gut microbiota composition [8, 9].
The intestinal microbiota is primarily composed of six
microbial phyla including Firmicutes, Bacteroidetes, Acti-
nobacteria, Proteobacteria, Tenericutes and Fusobacteria.
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Notably, the dominant phyla occurring in the adult micro-
biota are represented by Firmicutes and Bacteroidetes
which together may constitute up to 90% of the total gut
microbiota [10]. Nevertheless, these values are different in
the infant intestine, where Actinobacteria and specifically
the genus Bifidobacterium are commonly in the majority
[11]. In addition, the adult gut microbiota is more com-
plex in terms of total bacterial numbers as well as encoun-
tered diversity of microbial taxa [11, 12]. A similar trend
was observed for the gut microbiota of the elderly popula-
tion [13], where the microbial intestinal communities ap-
pear to be less diverse. Collectively, the number of
bacterial cells residing in the human intestine was previ-
ously thought to be 10 times larger than the total number
of human cells [14], yet has recently been re-examined
and considerably reduced, revealing a 1:1 ratio [15]. Not-
ably, it has been postulated that the genetic arsenal consti-
tuted by the different microbes of the gut microbiota, i.e.,
the intestinal microbiome, is about 150 fold larger than
the human gene complement, with an estimated set of 3.3
million bacterial genes [16]. In addition, bacterial commu-
nities display quantitative and qualitative variations due to
several other variables such as chemical-physical host fac-
tors (e.g., pH, bile acids, transit time and mucus), environ-
mental factors (e.g., nutrients and medication) and
microbial factors (e.g., adhesion capability, bacterial en-
zymes, metabolic strategies) [1]. Another key force shap-
ing the diversity and composition of the gut bacterial
community is represented by bacteriophages, i.e. viral
predators of bacteria [17, 18].
Functions driven by the gut microbiota
The gut microbiota exerts a primary role in the break-
down of dietary, complex plant carbohydrates (that are
indigestible by host enzymes) and host-produced glycans
[e.g., mucin and human milk oligosaccharides (HMOs)],
as well as in the protection against pathogenic bacteria.
Furthermore, the gut microbiota is supposed to be essen-
tial for the correct development of the host immune sys-
tem [19]. In this context, there are growing indications
that the gut microbiota plays an important role in indu-
cing IgA production [20, 21], as well as in preserving the
homeostasis of several T cell populations in the gut, com-
prising regulatory T cells (Treg), T helper 1 (Th1), and 17
(Th17) cells [22], as well as MAIT cells [23].
Further metabolic functions of the gut microbiota en-
compass bile acid biotransformation, as well as produc-
tion of vitamins and synthesis of short-chain fatty acids
such acetate, propionate and butyrate. Furthermore,
other microbial products comprise lactate, ethanol, suc-
cinate, valerate, caproate, isobutyrate, 2-methyl-butyrate
and isovalerate. The most pronounced effects of these
metabolites are their trophic roles toward the intestinal
epithelium [24]. In particular, butyrate is the preferred
energy source for enterocytes.
Notably, commensal bacteria that normally reside in
the gut, i.e. the autochthonous or indigenous gut micro-
biota [25] are diverse between individuals and specific
species are known to possess distinct and in some cases
opposing roles. In this context, certain microbiota mem-
bers have been shown to influence Treg development,
whereas others promote Th17 development. Thus, a
well-adjusted autochthonous microbiota is essential to
drive the normal development of both mucosa-
associated lymphoid tissue and mucosal induced toler-
ance mechanisms based on the generation of Treg cells.
Colonization of mice deprived of the gut microbiota, i.e.
the germ free mice (GF), with Bacteroides fragilis has
been demonstrated to enhance the suppressive capability
of Tregs to promote anti-inflammatory cytokine produc-
tion [26]. In a similar fashion, the colonization of GF
mice with a mix of Clostridium strains increased the
production of IL10-producing Tregs in the colonic lam-
ina propria [27]. Besides, many other gut microorgan-
isms have been shown to modulate Treg production,
including microbial taxa that are commonly exploited as
health-promoting bacteria such as many members of the
Bifidobacterium genus [28, 29]. Conversely, Th17 cell re-
sponse in humans was demonstrated to be generated by
a particular and recently discovered bacterial group
named the segmented filamentous bacteria. Among this
latter group of bacteria it is worth mentioning Candida-
tus arthromitus, a microorganism known to colonize the
small intestine and capable of modulating IgA synthesis
[20, 21]. Recently, C. arthromitus has been demonstrated
to enhance the development of Th17 cells, while it has
also been shown to be involved in the etiology of a num-
ber of inflammatory and autoimmune diseases. Thus, a
microbiota that favors this microorganism has an impact
on the immune response and consequently on the devel-
opment of Th17-mediated inflammatory/autoimmune
diseases in the gut and at distal sites in the predisposed in-
dividuals. Recently, it has been shown that Prevotella histi-
cola modulates the systemic immune responses with the
decrease in pro-inflammatory Th1 and Th17 cells and an
increase in the frequencies of regulatory T cells, tolero-
genic dendritic cells, and suppressive macrophages [30].
The origin of the gut microbiota
It is generally perceived that the human gut is microbio-
logically sterile at birth, yet at that point will become
subject to extensive bacterial colonization (for review see
[18]). However, bacterial colonization is influenced by
both the delivery method, i.e. vaginal [31] versus caesar-
ian section [32], and by the feeding system, i.e. breast-
milk versus formula-milk [33]. It is believed that the
main modifications of the gut microbiota occurring
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during these first stages of life are attributed to antibiotic
treatments, GIT infections, as well as dietary modifica-
tions [34], as opposed to being stochastic [35].
Another important variable involved in the establish-
ment/development of the gut microbiota is represented
by the host genotype, although current scientific litera-
ture on this topic is still very scarce [36–39] making this
contribution not yet clearly defined and a subject of de-
bate. The environment is also considered to play a key
role in the establishment of the gut microbiota. In this
context, the impact of companion animals is worth men-
tioning as a valuable source of microorganisms that can
be transferred to the human host [40].
Dietary effects on the gut microbiota composition and
health are associated with variation of host genotypes
and environmental exposures. Growing evidences
propose that long-term diet is a primary force respon-
sible for shaping the gut microbiota. This hypothesis is,
for example, supported by co-evolution studies which
have demonstrated that gut microbiota composition and
functions are adapted to the diets of their corresponding
mammalian host [41, 42].
Other factors that are considered important for the es-
tablishment of the infant gut microbiota are those occur-
ring at prenatal stage, such as the mother’s age, length of
gestation (i.e. full-term versus pre-term), smoking habits,
probiotic use during pregnancy, intrapartum antibiotic
therapy, intrauterine environment or body mass index
[43, 44].
Gut microbiota as a possible predictor of the
human health
Recently, it has been documented that breast feeding
and vaginal delivery exert a positive influence on the
health status of the infant that may also impact posi-
tively later in life. Breast feeding and vaginal delivery
have been associated with lower incidence of immune
related disorders. Conversely, early perturbations of the
infant gut microbiota, such as those provoked by anti-
biotic therapies or other microbial stress factors, can
lead to chronic metabolic disorders. For instance, the
phylogenetic diversity of the newborn gut microbiota in-
creases gradually over time and modifications in com-
munity composition correlates with a very regular
temporal gradient. In contrast, some taxa show abrupt
shifts in abundance corresponding to changes in diet. In
fact, although the earliest infant gut microbiota seems to
be mainly enriched in genes facilitating lactose and lac-
tate utilization, functional genes involved in adult food
processing are already present before the introduction of
solid food, priming the infant gut for an adult diet.
Therefore, even modest introduction of solid foods,
typical during the weaning phase, causes a sustained
increase in the abundance of adult phyla (i.e.
Bacteroidetes), elevates fecal short chain fatty acid levels
and genes associated with carbohydrate utilization,
vitamin biosynthesis, and xenobiotic degradation, and
initiates the assembly of a more stable community com-
position. Also health conditions affect diversity, richness
and taxa, as observed in case of fever and/or after
administering antibiotics for bacterial infection where
diversity drops and taxa like Bifidobacterium and Bacter-
oides seem to disappear [34, 45]. Apparently, different
microbial colonization profiles are responsible for very
different physiological consequences on child health
[46]. Therefore, knowledge on the factors that shape the
developing gut microbiota from birth is critical to
develop/establish targeted strategies to minimize the
long-lasting effects of early disturbances in the human
microbiota [47].
Microbial colonization of the human gut is currently
believed to be one of the main determinants for priming
and programming of the human immune system, while
it is also presumed to drive correct development of the
intestinal tract and determine its metabolic activities.
These physiological processes are guided by constant
communication between members of the gut microbiota
and their host. Therefore, intestinal dysbiosis may dis-
rupt microbe-host dialogue, which in turn may trigger
long-lasting physiological effects and health disorders
[48]. Among these, extensive research has been per-
formed focusing on the potential effects of early life
microbiota and immune disorders. In this context, the
most convincing data originate from animal (murine)
studies, revealing a close relationship between early ex-
posure to microorganisms and development of immune
pathologies. Though this association had been recog-
nized for decades, these recent studies have contributed
to understand the mechanisms behind the long-term ef-
fects of the gut microbiota in influencing the immune
response. In this context, it has been shown that micro-
bial factors control the activity of chemokine ligand
CXCL16, which modulates the increase of invariant nat-
ural killer T cells in the colon and lungs, and that neo-
natal colonization of GF mice with a conventional
microbiota prevents their accumulation [49]. It has been
suggested that early-life microbiota imposes long-lasting
effects, and that the absence of such a microbial stimu-
lus may induce later-life inflammatory responses remin-
iscent of those seen in Inflammatory Bowel Disease
(IBD) and asthma [49]. The importance of a critical win-
dow within which disruption of the intestinal microbiota
may have long-lasting consequences in immune patholo-
gies has been suggested, and the ordered establishment
of appropriate cross-talk between gut commensals and
the intestinal mucosal surfaces has been highlighted.
This cross-talk is facilitated by host-microbial interac-
tions that are already believed to occur immediately
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following birth, suggesting that disease risk may be af-
fected during early life [50].
Atopic diseases (asthma and atopic eczema)
Among the Th2-mediated immune pathologies that are
linked to a particular microbiota establishment, atopy,
mainly in the form of asthma and atopic eczema, has
been associated with specific microbial features occur-
ring during the first days following birth.
There are several epidemiological studies suggesting
that early development of the infant gut microbiota af-
fects the risk of asthma at later stages in life [51]. This
has been linked to an inappropriate development of the
gut microbiota and the (associated) disturbance of im-
mune homeostasis during the first year of life [52].
Nevertheless, there is no scientific data showing a direct
association of specific microbial patterns in the early
stages of life with the development of asthma in later
life, since genetic, epigenetic and other environmental
factors also affect the development of this disease. How-
ever, it is becoming increasingly clear that the gut
microbiota exploits an important role in the perinatal
programming of asthma [53]. In this context, recent evi-
dence indicates that the risk of suffering from asthma is
higher in infants exhibiting a gut microbiota dysbiosis
during the first 100 days of life, and that such risk has
been associated with the presence of particular microbial
groups [18]. In this regard, a recent study assessing the
gut microbiota composition of 319 subjects of a Canad-
ian cohort, showed that infants at high risk of developing
asthma possess a significantly decreased relative abun-
dance of certain microbial genera such as Lachnospira,
Veillonella, Faecalibacterium and Rothia. In addition,
such differences in the abundance of bacteria taxa were
linked to levels of fecal bacterial metabolites. Inoculation
of these bacteria in GF mice reduced the airway inflam-
mation in their progeny, suggesting that these bacteria
possess a pivotal role in the etiology of asthma [54].
Moreover, low gut microbiota diversity during the first
month of life has been linked with a higher prevalence
of asthma in 7 years old children [55]. Similarly, lower
levels of Lachnospira and higher loads of Clostridium
spp. at 3 months have been positively linked with asthma
risk by 4 years of age, suggesting that the ratio between
these two bacteria could be used as a biomarker for
asthma development [56].
Chronic recurring atopic eczema is the principal clin-
ical sign for atopic disease during the first years of life
[57]. The association between the gut microbiota and
atopic eczema has been established through the use of a
culture-independent PCR-based approach, which re-
vealed differences in the gut microbiota composition at
the age of 1 month, a period that precedes the manifest-
ation of atopic symptoms within the first 2 years of life.
Specifically, the occurrence of Escherichia coli has been
linked with a higher risk of developing eczema, and the
presence of Clostridium difficile was associated with sev-
eral atopic outcomes, including eczema, wheeze and al-
lergic sensitization [58]. Such findings were confirmed in
another large study involving 646 infants, in which an
association was detected between colonization by E. coli
and development of IgE-associated eczema within the
first year of life [59]. Subsequent studies indicate that a
reduced microbial diversity of early life microbiota dir-
ectly correlates with later development of atopic eczema
[60–62]. Interestingly, it has recently been highlighted
that the butyrate-producing bacteria Coprococcus eutac-
tus is implicated in the reduction of the severity of ec-
zema [63]. Although these data do not associate a
particular early microbiota profile with a decrease of
atopic eczema ailment, it nonetheless indirectly points to
the potential protective role of butyrate-producer bac-
teria against the development of atopic eczema. Notably,
another study pointed out that a low load of butyrate-
producers appears to commonly precede the develop-
ment of atopic eczema [64].
As previously underlined, low microbial diversity dur-
ing the early stages of life and/or the lack of particular
microorganisms may play a critical role in the subse-
quent development of allergic diseases. This has been
highlighted by a recent study where a correlation be-
tween the absence or the reduction of taxa like Bifido-
bacterium, Akkermansia or Faecalibacterium and
childhood atopy, and asthma, was observed [65]. Thus,
there is a “window of opportunity,” aligning with the es-
tablishment of an early microbial colonization, where
microbiota modulation may prevent disease, for example
through the use of probiotics. In this context, it has been
shown that babies that were colonized with Bifidobacter-
ium breve during the early post-natal period (1 week and
3 months) displayed a reduced risk of developing eczema
in the first year of life [66]. A small number of innova-
tive studies reported a long-term prevention of atopic
eczema by probiotics provided to mothers during preg-
nancy or postnatally to infants [57, 67, 68]. However,
caution should be taken in the biological significance of
these results since some of these findings could not be
reproduced with different cohorts though employing the
same probiotic strains [69]. In relation to this, consider-
ing the scientific evidence generated in various human
clinical trials using probiotics, the World Allergy
Organization has recently published recommendations
about the use of probiotics in the prevention of allergy.
These guidelines concluded that, although current evi-
dence likely supports a net benefit related to the use of
probiotics in eczema prevention, there is not enough evi-
dence supporting the recommendation of probiotics for
the reduction of allergy risk in children [70].
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Food allergy
Intestinal bacteria are critical for regulating allergic re-
sponses to dietary antigens and this suggests that inter-
ventions modulating bacterial communities are
therapeutically relevant for food allergy. According to a
very recent study, the presence of a Clostridiales taxa
Anaerostipes (i.e., in particular the species Anaerostipes
caccae) has been associated with a reduction of the risk
of food allergy in infant [71]. Furthermore, gut micro-
biota composition seems to play a role in food allergy
resolution in infants suffering from cow’s milk protein
allergy [72].
Metabolic disorders
Gut microbiota composition and function has been
linked with obesity and obesity-related disorders. By en-
hancing energy harvest, the so-called obesogenic micro-
biota modulates obesity behavior and peripheral
metabolism. It has been indicated that different factors
influencing the establishment of the gut microbiota dur-
ing infancy are responsible for obesity during subsequent
stages of life [73]. Microbiota-related obesity studies in
animal models, particularly in rodents, have increased
our understanding of the role of gut microbiota in driv-
ing metabolic disorders. Nevertheless, in recent years it
has become clear that extrapolation of results of animal
studies to humans comes with a lot of caveats, highlight-
ing the need to confirm such results by human clinical
trials [74]. It has been suggested that early microbial pat-
terns may predict overweight in children [75]. In this re-
gard, a large cohort study, involving 909 one-month-old
infants, revealed that levels of Bacteroides fragilis at 1
month of age are significantly associated with a higher
Body Mass Index (BMI) in children [76].
Appropriate conservation of the intestinal barrier
function seems to be pivotal for an adequate metabolic
balance. Thus, different factors disturbing the microbial
climax during early life play a key role in overweight,
obesity development and child adiposity in later life.
Among these factors, nutrition, maternal obesity, deliv-
ery mode, intestinal permeability, pathogenic infections
or antibiotic use, have been highlighted [77–80]. Fur-
thermore, the impact of the gut microbiota on brain de-
velopmental programming of obesity has also been
suggested [81].
Dietary manipulation with probiotic formulations
holds promise to prevent obesity [82]. However, in gen-
eral, clinical studies on a direct impact of probiotic inter-
ventions on weight development are very scarce, and
further epidemiological studies and clinical trials are
needed in order to obtain solid scientific evidence sup-
porting the use of probiotics in obesity prevention [83].
There is growing interest concerning the role of early-
life antibiotic therapy in the development of metabolic
diseases. In this regard, many murine studies have indi-
cated that gut microbiota perturbations caused by antibi-
otics during the establishment of the early infant gut
microbiota has long-lasting metabolic consequences, in-
cluding adiposity, insulin resistance, type 2 diabetes and
liver disease [84–86]. Epidemiological studies in humans
also demonstrated that antibiotic exposure is associated
with long-term metabolic effects including obesity in
children and adults. Studies with large infant cohorts
highlighted a link between early live antibiotic exposure
and childhood obesity [87]. Furthermore, it has been
suggested that disturbances of the intestinal microbiota
caused by antibiotics, either during prenatal and postna-
tal periods, may increase the risk of becoming obese [88,
89]. However, further evidences from epidemiological
studies are necessary to establish a definitive link be-
tween early life antibiotic-induced dysbiosis and the sub-
sequently development of metabolic disease.
Other diseases
Dysbiosis occurring during the early stages of life has
also been related with other long-lasting effects, such as
Inflammatory Bowel Disease (IBD), Irritable Bowel Syn-
drome (IBS) and type 1 diabetes (T1D).
T1D is an autoimmune disease caused by the destruc-
tion of insulin-producing beta cells. T1D may influenced
by several environmental factors, and the gut microbiota
has been put forward as a possible instigator in the de-
velopment of this disease. Longitudinal studies in pa-
tients with T1D have revealed a lower diversity and
significant differences in the ratio of Firmicutes and Bac-
teroidetes, as well as a significant reduction in the load
of the butyrate-producer Faecalibacterium prausnitzii in
diabetic children [90]. Indeed, butyrate-producing bac-
terial species are more abundant in non-diabetic chil-
dren, and it has been suggested that these bacteria play a
key role in reducing the risk of developing T1D [91].
Furthermore, how early intestinal colonization can im-
pact on the subsequent progression of T1D has also
been studied. Notably, it has been shown that microbiota
perturbations during early infancy may establish a pro-
inflammatory environment promoting the development
of autoimmune disease [92].
Diseases involving intestinal inflammatory processes
have also been related to early microbiota colonization
in infants. The fact that the human intestinal immune
system is educated during the first stages of life by the
microbial colonization has clearly defined a link between
the pioneering gut microbial inhabitants, such as bifido-
bacteria, and subsequent intestinal inflammatory disease
[93–96]. However, data about the long-term effects of
early dysbiosis in the development of IBD and IBS in
childhood and adults are currently lacking and do not
allow the establishment of causality. Thus, future work
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involving animal models and human epidemiological
studies should be aimed at revealing microbe-mediated
immune and physiological responses that prevent or
promote these diseases.
The gut microbiota of infants and the threat of
neonatal pathologies
The neonatal stage can be characterized by a high risk of
nosocomial infections, which are commonly explained
by an immune system that it is still immature in early
life. Such disease issues are highly exacerbated in pre-
term infants, where the frequent use of catheters com-
monly trigger infections by Staphylococcus spp., as well
as E. coli and Klebsiella spp. [97–99]. In pre-term infants
this sepsis risk is aggravated, as well as the risk of devel-
oping Necrotizing Enterocolitis (NEC), representing a
very serious and frequently fatal disease [100]. In this
context, neonates developing NEC will also suffer from
sepsis, generally generated by a dominant member of the
gut microbiota, such as enterobacteria, of such pre-term
infants [98, 99].
So far, the etiology of NEC is still unknown, although
particular microorganisms have been proposed as causa-
tive agents [101]. Notably, it has been shown that the gut
microbiota of infants who develop NEC possesses a re-
duced bacterial diversity while at the same time containing
enhanced levels of potentially pathogenic microorganisms
[102, 103]. Nevertheless, the clinical trials that have been
performed have not yet identified a clear microbial profile
of dysbiosis, though such studies have frequently detected
a high load of Proteobacteria preceding NEC establish-
ment [104–107]. In addition, a markedly reduced level of
bifidobacteria has been observed and consequently the
lack of their potential protective role [108]. Specific meta-
bolic pathways associated with NEC have been described
[100] and metabolome deviations have been observed in
the serum of these infants [108].
As a general interpretation of the possible link between
NEC and gut microbiota, one may argue that an increased
immune response triggered by a high load of intestinal
Proteobacteria enhances the risk of bacterial translocation
and sepsis [109]. Many metagenomic-based studies have
highlighted a lower microbial diversity and low levels of
Bifidobacterium and Bacteroides, with a predominance of
enterobacteria, in infants who develop late onset sepsis as
compared with healthy counterparts [110–112]. Neverthe-
less, available scientific evidence is still limited and further
investigations are needed before drawing conclusions on
the role that early microbiota alterations play in determin-
ing the risk of infection and sepsis.
The core infant gut microbiota
The infant gut microbiota displays low diversity and its
structure is generally unstable and highly dynamic [113].
Conversely, the intestinal microbiota of adults is specific
to an individual and relatively stable [13]. However, bifi-
dobacteria are frequently detected in high amounts in
infants and consequently are considered a corner stone
member of the infant gut microbiota [11, 113–115].
The infant gut microbiota has by some authors been
classified into six microbiota types or groups, according
to the composition of the gut microbiota within which
certain bacterial taxa are abundantly present [18, 116].
Such infant gut microbiota groups encompass: Group 1
consisting of Enterobacteriales; Group 2 involving Bac-
teroidales and Verrucomicrobiales; Group 3 encompass-
ing all Selenomonadales as well as the Clostridiales
genera Pseudoflavonifractor and Subdoligranum and the
inter-individual level and delta-Proteobacteria Desulfovi-
brio; Group 4 including all Pasteurellales; Group 5 com-
prising most of the Clostridiales and Group 6 involving
the Clostridiales genera Anaerostipes and Faecalibacter-
ium, the Lactobacillales and Bifidobacteriales [116]. Even
though bifidobacteria are part of just one of the above
mentioned six groups, at the abundance level they repre-
sent, together with Veillonella, Streptococcus, Citrobac-
ter, Escherichia, as well as Bacteroides and Clostridium,
the microbial genera that dominate the infant core gut
microbiota [116].
Bifidobacteria as the key microbial group of the
infant gut microbiota
Bifidobacteria belong to the Actinobacteria phylum,
which were first isolated from feces of a breast-fed infant
by Tissier in 1899, and then named Bacillus bifidus
[117]. Bifidobacteria are widely distributed among ani-
mals whose offspring enjoy parental care, such as mam-
mals, birds, social insects [118]. Consequently, the cause
for this intriguing ecological distribution may be ex-
plained to direct transmission of bifidobacteria from
mother/carer to offspring [119, 120]. Bifidobacteria have
also been retrieved in three other ecological niches, in-
cluding human blood (Bifidobacterium scardovii), as well
as sewage (e.g. Bifidobacterium minimum and Bifidobac-
terium thermacidophilum) and food products (e.g. Bifi-
dobacterium animalis subsp. lactis). Nevertheless, some
caution should be observed in the biological significance
of these “atypical” ecological origins, since it is plausible
that the identification of bifidobacteria in these environ-
ments is due to fecal contaminations [121].
Amongst the 80 (sub) species bifidobacteria so far rec-
ognized by the International Commission of Bacterial
Taxonomy [122], it is possible to identify bifidobacterial
species which elicit a rather broad host species prefer-
ence, i.e., engaging in a cosmopolitan lifestyle [122]. In-
triguingly, Bifidobacterium bifidum, Bifidobacterium
breve and Bifidobacterium longum are specifically identi-
fied in the human gut and have been shown to represent
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part of the dominant bacterial members of the gut
microbiota of breast-fed infants [120, 123].
Bifidobacterial population in the human gut
Bifidobacteria rapidly colonize the large intestine of in-
fants during the first weeks of life, believed to be at least
partly due to selection by breast or formula milk, as con-
firmed by metagenomic analyses [34, 114]. In breast-fed
infants, B. breve is the dominant species, followed by B.
bifidum, B. longum and B. adolescentis [11, 124].
The fecal microbiota of infants is generally character-
ized by high levels of bifidobacteria [11, 125], whose load
decreases after weaning and aging, though ecological
analyses based on Fluorescence in situ hybridization
(FISH) and metagenomic studies have estimated that
their presence in the adult large intestine could reach
4.3 ± 4.4% of fecal microorganisms [12, 126]. It has been
estimated that the bifidobacterial communities of the
adult colon are dominated by B. adolescentis as well as
B. catenulatum and B. longum subsp. longum species
[127, 128]. Notably, metagenomics as well as culturomic
approaches showed that each subject possesses a specific
population of colonic bifidobacteria that is in agreement
with the large inter-variability of the whole intestinal
microbiota previously described [12, 35]. In addition,
cataloguing of bifidobacterial communities of both the
infant and the adult human led to the identification of
many novel bifidobacterial 16S rRNA gene sequences,
which are presumed to represent as yet undefined novel
bifidobacterial species [120, 128].
As mentioned above, B. bifidum is among the first col-
onizers of the human gut, reaching high numbers in the
infant gut, but also detected at very low levels in adults
[11]. Thus, B. bifidum species is considered a key mem-
ber of the human intestinal bifidobacterial population
and of the infant core microbiota of infants.
The case of Bifidobacterium bifidum PRL2010 as
an intriguing example of a microbial inhabitant of
the infant gut microbiota
As described above B. bifidum was the first bifidobacter-
ial species to be characterized at the beginning of the
last century by Tissier [129], having been isolated from
stool samples of a breast-fed infant. Since then a grow-
ing number of bifidobacterial species have been identi-
fied and characterized, with some of these, in particular
B. bifidum strains have been shown to be dominant in
the infant gut [120] and predicted to be vertically trans-
mitted from mothers to corresponding children [120,
130]. In this context, in 2010 a B. bifidum strain, named
PRL2010, was isolated from the fecal sample of a 3
month-old, Italian, healthy, breast-fed infant. Since then,
many scientific publications related to this strain have
been generated, providing a very detailed characterization
of its ecology, physiology and genetic features, in addition
to its cross-talk activities with its host and other members
of the infant gut microbiota [118, 131–148].
The ecological role of PRL2010 within the infant gut
microbiota
As described above bifidobacteria constitute one of the
first microbial colonizers of the infant gut [18]. Remark-
ably, the human gut at birth is assumed to be a micro-
biologically sterile environment, which is exposed to
bacterial colonization of microorganisms, such as bifido-
bacteria, that are maternally acquired by vertical trans-
mission including direct mother-baby contact at birth
yet also through breastfeeding [18]. Nevertheless, in case
of “non-natural” settings like a Caesarian delivery or bottle
feeding, the large intestine of a baby may be prone to ab-
errant bacterial colonization by environmental microor-
ganisms including pathogens that may provoke long
lasting health effects on the host. Interestingly, a probiotic
intervention at this stage of life may be crucial in terms of
preventing the establishment of a dysbiotic microbiota
with its associated negative health implications.
In this context, it has been shown that B. bifidum
PRL2010 exert an altruistic syntrophic effect to benefit
nutrients to the gut microbiota, particularly with respect
to other members of (healthy) infant-associated bifido-
bacterial communities [144]. In vivo murine trials in-
volving B. bifidum PRL2010 revealed that, in contrast to
other bifidobacterial strains like B. longum subsp. intan-
tis ATCC15697, PRL2010 possesses cross-feeding fea-
tures that support growth of other bifidobacteria [144].
The cross-feeding characteristics of B. bifidum PRL2010
were further evaluated through in vitro assays aimed at
exploring how co-cultivation of PRL2010 cells with other
bifidobacterial strains belonging to various species en-
hanced growth abilities of these latter as compared to
growth yields achieved when these bacterial strains were
cultivated on their own. This interesting biological fea-
ture of B. bifidum PRL2010 was observed when this
strain was cultivated on host-glycans like mucin and
HMOs [132, 133] and on plant-derived carbohydrates
like starch and xylan [143]. It has been shown that B.
bifidum PRL2010 releases rather simple glycans from
these complex carbohydrates so that these become ac-
cessible to other members of the (bifido) bacterial com-
munity. Conversely, the latter bacteria do not possess
the necessary enzymatic arsenal to directly metabolize
these complex carbohydrates by themselves.
The occurrence of B. bifidum PRL2010 cells in the
cecum of mice has been shown to promote an expansion
of the murine intestinal glycobiome, representing the
complete genetic arsenal requested for the metabolism of
carbohydrates, toward enzymatic breakdown of both
plant- and host- derived carbohydrates [144]. Remarkably,
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B. bifidum PRL2010 modulates the murine gut microbiota
by an increase of those microbial groups responsible of
the production of Short Chain Fatty Acids (SCFA) such as
butyrate and propionate [144].
Another interesting cross-talk activity between B. bifi-
dum PRL2010 and other microbial members of the hu-
man gut microbiota is represented by the ability of this
strain to synthetize extracellular proteins, known as
sortase-dependent pili, particularly when it is residing in
the mammalian gut [118, 135]. Interestingly, these pro-
teinaceous appendages, apart from playing an important
role in driving the interaction of bacteria with the host
(see below), also appear to be crucial in modulating
physical contacts with other bifidobacterial cells and
other human gut commensals through the establishment
of cell aggregation [141].
Genetic adaptation of B. bifidum PRL2010 to the human
gut
The human gut mucosa is covered by a thick mucin
layer, which provides protection against injury and pre-
vents penetration by intracellular pathogens. Further-
more, mucin may exploit a prebiotic role by stimulating
the growth of particular members of the autochthonous
gut microbiota [145]. The breakdown of mucin, which is
expected to diminish the thickness of the mucin layer
and consequently decrease the protective barrier covering
the intestinal mucosa, may be considered as an undesired
event. However, one may also consider degradation as an
evolved “host-settler mechanism”. In this context, the pro-
duction of mucin in the human colon generally only begins
several months following birth, reaching its full synthesis
level at about 1 year of age [149]. Notably, mucin break-
down as driven by certain human gut commensals, includ-
ing B. bifidum may consequently trigger the secretion of
additional colonic mucin, thus recovering or even increasing
the thickness of the total load of mucus layer present on the
mucosa, thereby reinforcing the epithelial barrier function,
which represents an important feature especially in those
subjects affected by irritable bowel syndrome [150].
Amongst the bifidobacterial communities, strains be-
longing to the B. bifidum species are currently the only
bifidobacteria that are known to actively metabolize and
actually grow on mucins [146, 151]. Genome sequencing
of B. bifidum PRL2010 combined with functional ana-
lyses such as proteome and transcriptome analyses,
allowed to precisely define the genetic determinants re-
sponsible for the metabolism of these host-glycans [146].
According to the Carbohydrate Active Enzymes (CAZy)
system, the genome of B. bifidum PRL2010 encodes
members of two carbohydrate-binding module (CBM)
families, CBM32 and CBM51, which were predicted to
link to carbohydrate residues encountered in the mucin
core structure [152]. Notably, among all assessed
bifidobacteria such CBM32 and CBM51 encoding mod-
ules were identified only in the chromosomes of B. bifi-
dum [145].
Chemically similar host-glycans are represented by
HMOs, which are consequently efficiently degraded by
many members of the B. bifidum species, including
PRL2010 [123, 146].
In addition, in depth investigation of the genetic ar-
senal needed for the uptake of carbohydrates of B. bifi-
dum PRL2010 highlighted rather modest carbohydrate
transport abilities, which may suggest an interesting gen-
etic strategy for efficient colonization and survival of this
strain in the infant gut [140].
Another key example describing the genetic adaptation
of B. bifidum PRL2010 to the human intestine is consti-
tuted by the ability of B. bifidum PRL2010 cells to ad-
here to human cell lines like Caco2 and HT29
monolayers [136]. Notably, the adhesion index of B. bifi-
dum PRL2010 cells to these human monolayers is con-
siderably higher as compared to other extensively
exploited bifidobacterial probiotic strains like Bifidobac-
terium animalis subsp. lactis BB12 [136]. The molecular
mechanism driving this intriguing behavior of B. bifidum
PRL2010 has been discovered [135], being represented
by the production of sortase-dependent pili modulating
both adhesion to human enterocytes through extracellu-
lar matrix (ECM), and being considered crucial for
microbe-host cross-talk [135, 153]. Remarkably, pilus
production appear to be enhanced when B. bifidum
PRL2010 cells are located in their natural ecological niche,
i.e., the human gut, or when this habitat is simulated
under in vitro conditions, e.g., by cultivating PRL2010 in
the presence of complex carbohydrates commonly found
in the human large intestine [135, 141].
The pili of B. bifidum PRL2010 cells have also been re-
ported to modulate innate immunity of the host [135,
138]. According to the latter work, pili of B. bifidum
PRL2010 are implicated in the developmental program-
ming of the host immune system during infancy, being
involved in the imposition of barriers that specifically act
against possible bacterial infections.
Other extracellular structures of B. bifidum PRL2010
cells such as teichoic acids, represent possible candidates
for promoting the interaction of this strain with the host
[147]. However, these data are merely supported by
comparative genome analyses and further in vivo valida-
tions of their possible host interaction activities are
therefore needed.
The interaction of B. bifidum PRL2010 with the host
immune system
It has already been established that members of the B.
bifidum species have been playing essential roles in the
evolution and maturation of the immune system of the
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host, which is immature in neonates [154]. It has been
shown that B. bifidum strains, including PRL2010, in
contrast to other bifidobacterial taxa, may cause signifi-
cantly enhanced production of cytokine IL-17 [146, 154].
The interaction of B. bifidum PRL2010 cells with the
host immune system has been investigated in consider-
able detail through the use of both an in vitro cell line-
and a murine- model [138]. Notably, the overall host-
response scenario driven by B. bifidum PRL2010 cells
can be explained as a local pro-inflammatory response,
modulating the immune system. Simultaneously, B. bifi-
dum PRL2010 cells trigger an attenuation of the pro-
inflammatory response by down-regulating particular
chemokines like the heat shock proteins, while up-
regulating defensin and tight junction genes [138]. In
addition, ELISA experiments demonstrated that expos-
ure to B. bifidum PRL2010 cells activates synthesis of
IL-6 and IL-8 cytokines, presumably through NF-kb acti-
vation [138].
The roles of PRL2010 on the mucosal integrity have
been evaluated through an in vivo murine model simulat-
ing an ulcerative colitis status [138]. In the latter study,
the pretreatment with B. bifidum PRL2010 cells was
shown to elicit increased expression of tight junction-
encoding genes, being associated with a marked reduction
of all colitis-associated histological parameters [138].
Conclusions
Genetic and environmental factors are known to modu-
late the composition of the gut microbiota, which is be-
lieved to exert key roles in modulating the immune
response at both intestinal and extra-intestinal sites, as
well as in controlling the development of certain types
of autoimmune and allergic diseases and particular types
of cancers. The relationship between gut microbiota, im-
munity and disease is very intricate, since the same com-
mensal bacteria can induce either a protective response
or a pathogenic/inflammatory response, depending on
the susceptibility of the individual. Notably, despite nu-
merous efforts the specific microorganisms contributing
to either the aetiology and/or protection from different
types of diseases, i.e. those microbes that could therefore
be employed as microbial biomarkers, have not yet been
fully characterized. However, in the case of the infant
gut microbiota, it has been demonstrated that a drastic
reduction of its complexity and a reduction of the bifido-
bacterial load is commonly associated with diseases and or
disorders that are established later in life [18]. Thus, pre-
cise evaluation of the intestinal microbiota composition of
the newborn will in the not too distant future become a
valuable clinical procedure in order to predict and possible
prevent the development of diseases/disorders.
The discovery of microbial biomarkers and effective
prebiotic/probiotic compounds will be crucial in order
to establish biotherapeutical protocols for the prevention
and treatment of gut microbiota-mediated diseases.
There is a growing interest by the scientific community
in the exploitation of a next generation of probiotic bac-
teria, i.e., those whose health-promoting activities are
supported by rigorous scientific/genetic proof and pos-
sessing the ability to modulate the gut microbiota. Such
probiotic applications may be highly effective in environ-
ments where the natural microbial complexity is rather
simple, such as the infant gut microbiota. There is a
growing scientific literature describing the use of probio-
tics for the treatment of acute gut infectious diseases, in
necrotizing enterocolitis, acute respiratory infections and
recurrent urinary tract infections. However, there is still a
large gap of knowledge about the molecular basis support-
ing these potential beneficial effects of probiotic bacteria
as well as about the adequate dosages, duration of treat-
ment and safety of such probiotic formulations [155].
Apart from the use of probiotic strains, such as B. bifi-
dum PRL2010, for infants, another potential application
of these probiotic bacteria includes the treatment of
women during pregnancy. Such probiotic therapy may
be crucial in order to colonize the mother’s gut by prior
the delivery and thus to guarantee the settling of an ap-
propriate bifidobacterial community that will be verti-
cally transmitted to the newborn at birth. Nevertheless,
rigorous clinical testing involving these bacteria need to
be performed before meaningful probiotic claims (for
humans) can be made.
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